Molecular Biology and Prevention of Endometrial Cancer
Abstract
To increase our understanding of the molecular aberrations associated with endometrial carcinogenesis and the biologic mechanisms underlying the protective effect of oral contraceptive therapy. Methods: 1) Both cDNA and oligonucleotide microarray analysis was performed on a panel of endometrial cancers. 2) A subset of adenocarcinomaa cases from the International DES Registry was analyzed for MSI and the poor quality of the DNA from many of these cases prohibited an adequate analysis of the entire set. The cases are currently being evaluated for PTEN expression. 3) We analyzed the Cancer and Steroid Hormone (CASH) database to determine if higher progestin potency confers a more protective effect against endometrial cancer. 4) Finally, we are in the process of analyzing the endometrium form cymologous macaques that were exposed to long term progestins as part of the three year randomized controlled trial. Results: 1) Different histological types of endometrial cancer have unique genomic expression patterns. 2) The rate of MSI in cancers that develop after a perinatal exposure to DES is lower than previously reported. 3) The potency of the progestin in most oral contraceptives appears adequate to provide a protective effect against endometrial cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2003
- Accession Number
- ADA423688
Entities
People
- George L. Maxwell
Organizations
- Henry M. Jackson Foundation for the Advancement of Military Medicine